Correspondence 0001193125-23-140850 from TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc.
Date: May 10, 2023 · CIK: 0001783328 · Accession: 0001193125-23-140850
AI Filing Summary & Sentiment
File numbers found in text: 333-268260
Letter
TScan Therapeutics, Inc.
830 Winter Street
Waltham, Massachusetts 02451
May 10,
Via EDGAR Transmission
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Re: TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-268260)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), TScan Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to May 12, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact William D. Collins of Goodwin Procter LLP at (617) 570-1447.
Sincerely,
TScan Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 May 10, 2023 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-268260) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), TScan Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to May 12, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact William D. Collins of Goodwin Procter LLP at (617) 570-1447. Sincerely, TScan Therapeutics, Inc. /s/ Brian Silver Name: Brian Silver Title: Chief Financial Officer Cc: William D. Collins, Esq., Goodwin Procter LLP